Wolfe Research Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $150

Benzinga · 3d ago
Wolfe Research initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform rating and announces Price Target of $150.